v3.26.1
Condensed Consolidated Statements of Equity (Deficit) (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2024 $ 3,364 $ 18 $ (8,201) $ 21,333 $ (7,900) $ (1,925) $ 39
Beginning balance (in shares) at Dec. 31, 2024   1,765          
Acquisitions of businesses, net of cash acquired              
Net earnings attributable to AbbVie Inc. 1,286 $ 0 0 0 1,286 0 0
Other comprehensive income (loss), net of tax 183 0 0 0 0 183 0
Dividends declared (2,913) 0 0 0 (2,913) 0 0
Purchases of treasury stock (963) $ 0 (963) 0 0 0 0
Purchases of treasury stock (in shares)   (5)          
Stock-based compensation plans and other 502 $ 0 27 475 0 0 0
Stock-based compensation plans and other (in shares)   6          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Mar. 31, 2025 1,462 $ 18 (9,137) 21,808 (9,527) (1,742) 42
Ending balance (in shares) at Mar. 31, 2025   1,766          
Beginning balance at Dec. 31, 2025 (3,228) $ 18 (9,146) 22,495 (15,493) (1,144) 42
Beginning balance (in shares) at Dec. 31, 2025   1,768          
Acquisitions of businesses, net of cash acquired              
Net earnings attributable to AbbVie Inc. 695 $ 0 0 0 695 0 0
Other comprehensive income (loss), net of tax (9) 0 0 0 0 (9) 0
Dividends declared (3,074) 0 0 0 (3,074) 0 0
Purchases of treasury stock (1,489) $ 0 (1,489) 0 0 0 0
Purchases of treasury stock (in shares)   (6)          
Stock-based compensation plans and other 491 $ 0 24 467 0 0 0
Stock-based compensation plans and other (in shares)   5          
Change in noncontrolling interest 2 $ 0 0 0 0 0 2
Ending balance at Mar. 31, 2026 $ (6,612) $ 18 $ (10,611) $ 22,962 $ (17,872) $ (1,153) $ 44
Ending balance (in shares) at Mar. 31, 2026   1,767